HiSiaddi is an innovative foreign trade service provider driven by dual engines of technology transformation and foreign trade services. We have established a "1+2+3+4=1" service system and can supply raw materials of Coriolus Versicolor Extract from multiple well-known original manufacturers.
As a foreign trade enterprise with independent R&D capabilities, HiSiaddi has repeatedly delivered formula optimization solutions and application improvement suggestions for Coriolus Versicolor Extract by leveraging technological cooperation with manufacturers and precise market insight. Below is a case study of formula optimization consulting for Coriolus Versicolor Extract.
Please contact HiSiaddi customer service if you require further formula optimization consulting services.
The buyer is BioGreen Pharm Co., Ltd., headquartered in Seoul, South Korea — a mid-to-high-end domestic biopharmaceutical enterprise specializing in R&D and production of tumor adjuvant dietary capsules and immune oral liquids. Its products are sold in large premium pharmacy chains across South Korea, multiple private oncology rehabilitation hospitals in Seoul and high-end wellness centers on Jeju Island. Raw materials comply with KFDA access standards, USP Pharmacopoeia and EU EC396 regulation covering 226 pesticide residue items.
The company previously imported pharmaceutical-grade Coriolus Versicolor Extract from Northern Europe year-round, yet skyrocketing overseas raw material prices and extended ocean delivery lead times pushed it to source customized raw materials from China, with an annual total procurement volume of 12.9 tons split into two specifications:
1. Refined powder for capsules: Total polysaccharides ≥30%, β-glucan ≥18%, no starch or maltodextrin fillers;
2. Cold-water-soluble modified powder for oral liquids: No precipitation or stratification after 90 days of storage at 4°C.
After independently sourcing raw materials from three domestic plant extract manufacturers and feeding them into its South Korean GMP production line, multiple technical failures emerged during production and formula compatibility, delaying the new product launch plan by 68 days. Total losses from discarded raw materials, production line shutdowns and third-party testing amounted to 312 million South Korean Won. Original suppliers only possessed basic crude extraction capacity and could not conduct full-chain troubleshooting from raw material, extraction process, powder physical properties and end-formula dimensions. The client entrusted HiSiaddi to form a technical team of plant extract engineers, formulation specialists and physical-chemical testing specialists to conduct full-link troubleshooting and deliver a technical optimization solution.
Previous suppliers randomly mixed wild-simulated forest Coriolus Versicolor from Changbai Mountain, Northeast China with rapid-cycle greenhouse-grown fungi for feeding. Forest premium Coriolus Versicolor delivers an intrinsic polysaccharide base of 12%–14%, while greenhouse fungi only reach 5%–7%. Suppliers increased the proportion of cheap greenhouse fungi when raw material purchase prices dropped, resulting in unstable total polysaccharide levels of 22.8%–31.5% in finished products, with β-glucan mostly below 15% — failing to hit the customized minimum threshold of 18%. The South Korean pharmaceutical plant could not calculate fixed feeding ratios based on standardized active ingredient content, leading to drastic fluctuations in active components per capsule during mass production and seizure of multiple batches during random KFDA inspections. Greenhouse cultivation imposes loose pesticide application management, with heavy metal and pesticide residue indicators for partial raw materials approaching South Korean regulatory limits.
β-glucan is temperature-sensitive and prone to hydrolytic cleavage above 70°C. Conventional manufacturers adopt prolonged boiling extraction at 92°C, causing β-glucan degradation losses exceeding 32%. Even with 100% premium forest-grown Coriolus Versicolor as feedstock, key indicators still fail to meet standards. Open atmospheric extraction tanks lack closed organic solvent recovery equipment, leading to methanol residues generally exceeding 5300 ppm — far above the client’s internal control limit of 2500 ppm. This triggers gelatin shell softening and leakage during capsule filling, pushing the product rejection rate up to 27.8%.
Factories only produce unified crude powder via spray drying without modification tailored for capsules and oral liquids:
· Capsule workshop: Uneven powder particle size with excessive fine particles, an angle of repose exceeding 47%, electrostatic agglomeration and silo bridging blockages that force frequent shutdowns of automatic filling machines for cleaning; single capsule content error peaks at 7.7%, violating the ±2% control standard set by South Korean Pharmacopoeia.
· Oral liquid workshop: Crude extract features extremely poor water solubility, forming cloudy liquids upon cold-water dosing and off-white flocculent precipitates after 7 days of low-temperature storage, destroying the colloidal system and rendering entire batches of beverages unqualified for retention testing.
The client’s mature oral liquid formula combines Coriolus Versicolor extract with zinc salts and complex vitamins. Crude extracts retain large amounts of plant protein, crude fiber and free colloid impurities; trace heavy metal ions catalyze vitamin oxidation. After 42 days of accelerated ambient testing, the liquid turns light yellowish-brown to dark brown, with active polysaccharide losses exceeding 15% — failing to meet the 24-month shelf-life requirement. Three rounds of auxiliary material ratio adjustments and vitamin raw material replacements only slightly delayed discoloration without eliminating the root cause.
Loose control of conventional spray drying processes leads to raw material moisture levels generally above 1.45%. Warehouses across South Korea maintain ambient humidity at approximately 51%, causing raw materials to absorb moisture and cake within 2–3 days after unpacking. Caked powder blocks screening filters and adheres to capsule pressing molds, forcing the pharmaceutical plant to add extra manual crushing procedures and continuously raising production costs and defective product rates.
HiSiaddi’s technical team conducted on-site inspections of raw material production zones in Changbai Mountain, Jilin and partner refining factories, implementing rectifications in five sequential steps: source raw material control → extraction process upgrading → multi-stage resin deep impurity removal → specification-specific powder modification → formula co-optimization + warehousing specification guidance. Debugging was conducted across three phases: lab small samples, 55kg pilot trials and full-scale mass production.
HiSiaddi partnered with three standardized wild-simulated Coriolus Versicolor cultivation cooperatives under forests in Fusong, Changbai Mountain, signing annual exclusive harvest agreements. Harvests are limited to fully mature mushrooms picked manually in late autumn, with moldy fruiting bodies and greenhouse rapid-cycle fungi manually sorted out. Each batch of raw materials is accompanied by field pesticide application ledgers and origin filing documents. Raw materials are tested for intrinsic polysaccharide base upon arrival; entire batches with base levels below 11% are rejected, completely eliminating adulteration with low-quality fungi and locking in baseline active ingredient levels at source.
The high-temperature boiling process was eliminated and replaced with 42°C low-temperature staged percolation, gradient ethanol extraction, negative-pressure low-temperature concentration and two-stage macroporous resin serial refining, with full closed and light-shielded production to cap β-glucan degradation rate at 5.5% or below. Multi-stage resins sequentially remove crude fiber and macromolecular protein impurities, yielding finished products with stable total polysaccharides of 30.2%–30.8% and β-glucan of 18.1%–18.9%. A three-stage closed distillation recovery system is deployed to control methanol residues within 2320 ppm, resolving the issue of gelatin shell swelling and leakage.
1. Refined pharmaceutical powder for capsules: Low-temperature vacuum drying paired with nitrogen-protected ultrafine jet milling, optimizing the powder angle of repose to 33°±2° for uniform particle size and excellent flowability, with no additional anti-caking auxiliary materials added, fully compatible with high-speed automatic capsule filling equipment.
2. Cold-water-soluble modified powder for oral liquids: Low-temperature inclusion modification with filler-free β-cyclodextrin, with zero starch or maltodextrin added throughout the process. Post-modification powder dissolves instantly in cold water, forming clear solutions with no precipitation or stratification after 90 days of storage at 4°C.
Multi-stage resin treatment removes heavy metals and oxidation-promoting macromolecular impurities from raw materials. On the formula side, HiSiaddi remotely coordinated with the client’s South Korean R&D department to optimize feeding processes: separate pre-mixing and staged feeding of Coriolus Versicolor extract, trace elements and vitamin complexes to avoid direct catalytic oxidation triggered by metal ions. Post-optimization 90-day accelerated stability testing showed no discoloration, with active ingredient losses controlled within 3%, successfully passing South Korean shelf-life testing.
A segmented vacuum low-temperature dehydration process is adopted for finished products, stabilizing moisture levels of all batches at ≤0.5%. HiSiaddi compiled bilingual (Korean + English) warehousing guidelines requiring the client to maintain warehouse temperature at a constant 22°C and ambient humidity ≤40%. Raw materials are packed in independent vacuum nitrogen-filled aluminum foil bags for unpacking on demand, completely resolving moisture absorption and caking issues in high-humidity environments.
After four rounds of cross-border sample delivery, full-item physical and chemical pesticide residue testing at authoritative third-party laboratories in South Korea, plus 30 consecutive days of non-stop pilot production in the client’s GMP workshop, both customized raw material specifications fully passed KFDA pre-access audits. The first shipment of 3.9 tons of finished products was shipped from Shanghai Port to Incheon Port, passing random inspections by South Korean customs and the Ministry of Food and Drug Safety for one-time smooth warehousing. Post-production, capsule filling content error stabilized within ±1.8%, and product rejection rate plummeted from the original 27.8% to 1.03%. All batches of oral liquid retained stable quality without precipitation during low-temperature retention testing, enabling the delayed new product to complete South Korean product filing and officially launch in partner pharmacies and rehabilitation hospitals.
BioGreen Pharm formally signed a long-term annual procurement framework for 12.9 tons: 7.5 tons of specialized refined powder for capsules and 5.4 tons of water-soluble modified powder for oral liquids, scheduled for monthly production across 11 batches per year. Following stable cooperation, the client added customized low-impurity Coriolus Versicolor Extract for hospital skincare products in the subsequent year, with HiSiaddi taking full charge of overall process debugging, sample follow-up and technical optimization. Compared with raw materials imported from Northern Europe, overall customized procurement costs decreased by 30.6%, and sea freight lead time was shortened from 71 days to 21 days. Endorsed by this cooperation with a premium South Korean pharmaceutical enterprise, the domestic partner factory upgraded its standardized customized production line for Coriolus Versicolor, subsequently securing annual raw material orders from two equivalent pharmaceutical enterprises in Thailand and Singapore.
Most domestic plant extract manufacturers focus on low-cost crude processing of greenhouse-cultivated Coriolus Versicolor, featuring loose raw material sourcing control, outdated production processes and insufficient capabilities in powder modification and supporting formulation R&D. They lack systematic research on the thermosensitive properties of β-glucan and overseas pharmaceutical production operating conditions. Mid-to-high-end pharmaceutical enterprises represented by South Korea’s BioGreen Pharm specialize in end-product R&D and are well-versed in stringent KFDA regulations and mass production standards, yet lack familiarity with severe quality stratification among China’s Coriolus Versicolor raw materials and stark disparities in manufacturing process capabilities across factories. Independent direct sourcing frequently leads to mass production failures, delayed new product launches and substantial financial losses.
Leveraging upstream raw material resources and composite technical reserves covering plant extraction and pharmaceutical formulation, HiSiaddi built a closed-loop full-chain technical service system spanning raw material source to end production, bridging technical information gaps between Chinese and foreign parties and enabling high-end domestic Coriolus Versicolor Extract to steadily enter South Korea’s pharmaceutical-grade premium raw material supply chain.
Please contact HiSiaddi customer service if you require further formula optimization consulting services.
+86-13120989737 
info@hisiaddi.com 
English
